List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3598158/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European Heart Journal, 2006, 27, 1341-1381.	2.2	1,192
2	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. New England Journal of Medicine, 2016, 375, 2223-2235.	27.0	843
3	Mobilization of Bone Marrow-Derived Oct-4+ SSEA-4+ Very Small Embryonic-Like Stem Cells in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2009, 53, 1-9.	2.8	835
4	Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. New England Journal of Medicine, 2010, 363, 136-146.	27.0	608
5	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet, The, 2008, 372, 1163-1173.	13.7	607
6	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
7	Effects of the Direct Lipoprotein-Associated Phospholipase A ₂ Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque. Circulation, 2008, 118, 1172-1182.	1.6	492
8	Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. European Heart Journal, 2009, 30, 1313-1321	2.2	427
9	Acute and Late Outcomes of Unprotected Left Main Stenting in Comparison With Surgical Revascularization. Journal of the American College of Cardiology, 2008, 51, 538-545.	2.8	352
10	Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet, The, 2011, 378, 1940-1948.	13.7	321
11	Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 777-789.	2.9	296
12	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. European Heart Journal, 2017, 38, 3124-3134.	2.2	244
13	Value of the SYNTAX Score for Risk Assessment in the All-Comers Population of the Randomized Multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) Trial. Journal of the American College of Cardiology, 2010, 56, 272-277.	2.8	198
14	4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting Stents. Journal of the American College of Cardiology, 2014, 63, 1617-1625.	2.8	152
15	Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function. Circulation, 2006, 114, 2449-2457.	1.6	139
16	Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents. Circulation: Cardiovascular Interventions, 2015, 8, e002230.	3.9	122
17	Drug-Eluting Stent for Left Main Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 718-727.	2.9	121
18	Value of Age, Creatinine, and Ejection Fraction (ACEF Score) in Assessing Risk in Patients Undergoing Percutaneous Coronary Interventions in the †All-Comers' LEADERS Trial. Circulation: Cardiovascular Interventions, 2011, 4, 47-56.	3.9	109

#	Article	IF	CITATIONS
19	Treatment of Chronic Functional MitralÂValve Regurgitation With a Percutaneous Annuloplasty System. Journal of the American College of Cardiology, 2016, 67, 2927-2936.	2.8	105
20	The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. Journal of the American College of Cardiology, 2011, 57, 2221-2232.	2.8	101
21	The Prognostic Utility of the SYNTAX Score on 1-Year Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 432-441.	2.9	98
22	New-Onset Atrial Fibrillation After PCIÂorÂCABGÂforÂLeft Main Disease. Journal of the American College of Cardiology, 2018, 71, 739-748.	2.8	94
23	Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries. Circulation, 2018, 137, 166-183.	1.6	77
24	A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. Lancet, The, 2018, 391, 431-440.	13.7	70
25	Use of multidetector computed tomography for the assessment of acute chest pain: a consensus statement of the North American Society of Cardiac Imaging and the European Society of Cardiac Radiology. European Radiology, 2007, 17, 2196-2207.	4.5	63
26	Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial. Circulation, 2001, 103, 26-31.	1.6	53
27	The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial). American Journal of Cardiology, 2010, 105, 475-479.	1.6	49
28	The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. EuroIntervention, 2010, 6, 233-239.	3.2	49
29	Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. JACC: Cardiovascular Interventions, 2009, 2, 861-870.	2.9	48
30	Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. Lancet, The, 2018, 392, 1117-1126.	13.7	46
31	First generation versus second generation drugâ€eluting stents for the treatment of bifurcations: 5â€year followâ€up of the <scp>LEADERS</scp> allâ€comers randomized trial. Catheterization and Cardiovascular Interventions, 2016, 87, E248-60.	1.7	44
32	Comparison of Effectiveness of Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Ischemic Cardiomyopathy. American Journal of Cardiology, 2007, 99, 36-41.	1.6	39
33	Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney International, 2016, 90, 411-421.	5.2	38
34	The three year follow-up of the randomised "all-comers―trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). EuroIntervention, 2011, 7, 789-795.	3.2	36
35	2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical Practice. JACC: Cardiovascular Interventions, 2011, 4, 887-895.	2.9	32
36	Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry. Catheterization and Cardiovascular Interventions, 2008, 71, 51-57.	1.7	30

#	Article	IF	CITATIONS
37	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for LefT main) Tj ETQq1 1 0.78	4 3. 64 rgBT	D everlock
38	Use of changes in ST segment elevation for prediction of infarct artery recanalization in acute myocardial infarction. European Heart Journal, 1995, 16, 1207-1214.	2.2	21
39	Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injury. Thrombosis and Haemostasis, 2012, 108, 464-475.	3.4	21
40	Implantation of the biodegradable polymer biolimus-eluting stent in patients with high SYNTAX score is associated with decreased cardiac mortality compared to a permanent polymer sirolimus-eluting stent: two year follow-up results from the "Call-comers" LEADERS trial. EuroIntervention, 2011, 7, 605-613.	3.2	21
41	Experimental evaluation of pharmacokinetic profile and biological effect of a novel paclitaxel microcrystalline balloon coating in the iliofemoral territory of swine. Catheterization and Cardiovascular Interventions, 2014, 83, 325-333.	1.7	19
42	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. EuroIntervention, 2011, 6, 928-935.	3.2	19
43	Comparison of Stenting and Surgical Revascularization Strategy in Non-ST Elevation Acute Coronary Syndromes and Complex Coronary Artery Disease (from the Milestone Registry). American Journal of Cardiology, 2014, 114, 979-987.	1.6	16
44	A randomized comparison of elective high-pressure stenting with balloon angioplasty: Six-month angiographic and two-year clinical follow-up. American Heart Journal, 2000, 140, 264-271.	2.7	15
45	Controlled Reperfusion with Intravenous Bivalirudin and Intracoronary Abciximab Combination Therapy in the Porcine Myocardial Infarction Model. Thrombosis Research, 2012, 130, 265-272.	1.7	15
46	Intracoronary adiponectin at reperfusion reduces infarct size in a porcine myocardial infarction model. International Journal of Molecular Medicine, 2011, 27, 775-81.	4.0	14
47	2-Year Clinical Outcomes of anÂAbluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. JACC: Cardiovascular Interventions, 2019, 12, 1679-1687.	2.9	14
48	Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy. EuroIntervention, 2009, 5, 310-317.	3.2	14
49	A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial― American Heart Journal, 2017, 188, 11-17.	2.7	13
50	Percutaneous coronary intervention in the Occluded Artery Trial: Procedural success, hazard, and outcomes over 5 years. American Heart Journal, 2009, 158, 408-415.	2.7	12
51	Stenting and Adjunctive Delivery of Paclitaxel Via Balloon Coating Versus Durable Polymeric Matrix for De Novo Coronary Lesions: Clinical and Angiographic Results from the Prospective Randomized Trial. Journal of Interventional Cardiology, 2015, 28, 348-357.	1.2	12
52	Causes of hospitalisation and prognosis in patients with cardiovascular diseases – secular trends 2006-2014. SILesian CARDiovascular (SILCARD) database covering a population of 4.6 million subjects. Polish Archives of Internal Medicine, 2016, 126, 754-762.	0.4	12
53	Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model. Cardiology Journal, 2016, 23, 657-666.	1.2	12
	Rotational atherectomy in everyday clinical practice. Association of Cardiovascular Interventions of		

Rotational atherectomy in everyday clinical practice. Association of Cardiovascular Interventions of the Polish Society of Cardiology (Asocjacja Interwencji Sercowo-Naczyniowych Polskiego) Tj ETQq0 0 0 rgBT /Overl**o**ck 10 Tf **50** 57 Td (T

#	Article	IF	CITATIONS
55	Drug Delivery at the Aortic Valve Tissues of Healthy Domestic Pigs with a Paclitaxelâ€Eluting Valvuloplasty Balloon. Journal of Interventional Cardiology, 2009, 22, 291-298.	1.2	9
56	Usefulness of Stanford Scale of Intimal Hyperplasia Assessed by Intravascular Ultrasound to Predict Time of Onset and Severity of Cardiac Allograft Vasculopathy. Transplantation Proceedings, 2005, 37, 1343-1345.	0.6	8
57	Angiographic and clinical outcomes of drugâ€eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheterization and Cardiovascular Interventions, 2009, 73, 771-779.	1.7	8
58	Differences in vessel healing following delivery of everolimus or paclitaxel: a comparative experimental study using identical stent and biodegradable polymer platforms. EuroIntervention, 2014, 10, 724-731.	3.2	8
59	Percutaneous versus surgical revascularization for multivessel coronary artery disease: A single center 10 year followâ€up of SOS trial patients. Catheterization and Cardiovascular Interventions, 2009, 74, 420-426.	1.7	7
60	Renal Artery Stenting Associated With Improvement in Renal Function and Blood Pressure Control in Long-Term Follow-Up. Kidney and Blood Pressure Research, 2016, 41, 278-287.	2.0	7
61	A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly- <scp>l</scp> -Lactide Biodegradation Kinetics From Stent-Polymer Matrices. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 93-99.	2.0	7
62	Effects of renal sympathetic denervation on blood pressure and glycaemic control in patients with true resistant hypertension: results of Polish Renal Denervation Registry (RDN-POL Registry). Kardiologia Polska, 2016, 74, 961-968.	0.6	7
63	Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Disease: The Endless Debate. Journal of the American College of Cardiology, 2008, 52, 582-584.	2.8	6
64	Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: Insights from a multicenter, propensity scoreâ€matched registry. Catheterization and Cardiovascular Interventions, 2013, 82, E155-62.	1.7	6
65	An optical coherence tomography study of neointimal morphology and strut coverage at different time intervals from implantation of biodegradable polymerâ€coated sirolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2018, 92, 302-309.	1.7	5
66	Longâ€ŧerm results of cephalad arteries percutanoeus transluminal angioplasty with stent implantation (The CAPTAS registry). Catheterization and Cardiovascular Interventions, 2012, 79, 532-540.	1.7	4
67	Longâ€ŧerm results of plaque excision combined with aggressive pharmacotherapy in highâ€Risk patients with advanced peripheral artery disease (SAVE a LEG registry). Catheterization and Cardiovascular Interventions, 2013, 82, E244-50.	1.7	4
68	Treatment of symptomatic coronary artery disease in patients with endâ€stage renal disease on hemodialysis with paclitaxelâ€eluting <scp>TAXUS</scp> stent. Hemodialysis International, 2015, 19, 402-411.	0.9	3
69	A Novel Peritoneum Derived Vascular Prosthesis Formed on a Latex Catheter in an SDF-1 Chemokine Enriched Environment: A Pilot Study. International Journal of Artificial Organs, 2015, 38, 89-95.	1.4	3
70	Five-year outcomes of chronic total occlusion treatment with a biolimus A9-eluting biodegradable polymer stent versus a sirolimus-eluting permanent polymer stent in the LEADERS all-comers trial. Cardiology Journal, 2016, 23, 626-636.	1.2	3
71	Selected adipokines and thickness of the intima-media complex in patients with systemic lupus erythematosus. Kardiologia Polska, 2018, 76, 917-919.	0.6	3
72	Effects of local intracoronary paclitaxel delivery using the Remedy transport catheter on neointimal hyperplasia after stent implantation in a porcine model. Cardiovascular Revascularization Medicine, 2011, 12, 82-89.	0.8	2

#	Article	IF	CITATIONS
73	Safety and feasibility of sameâ€day early discharge after endovascular revascularization of lower extremities in elderly. S <scp>ENIORâ€ER</scp> registry. Catheterization and Cardiovascular Interventions, 2018, 91, 515-520.	1.7	2
74	State-of-the-art of transcatheter treatment of aortic valve stenosis and the overview of the InFlow project aiming at developing the first Polish TAVI system. Cardiology Journal, 2017, 24, 685-694.	1.2	1
75	The new Polish stent Chopin. Assessment of safety and efficacy in the treatment of de-novo coronary lesions using percutaneous angioplasty. Kardiologia Polska, 2005, 62, 451-9; discussion 460-1.	0.6	1
76	Taxcor for the prevention of restenosis. Polish multicentre observational study to assess the efficacy and safety of the Genius TAXCOR I stent. Postepy W Kardiologii Interwencyjnej, 2011, 4, 285-291.	0.2	0
77	Giant aneurysm in medial anterior descending artery: treatment with two endovascular stent grafts on bare metal stent scaffold. Postepy W Kardiologii Interwencyjnej, 2011, 2, 173-177.	0.2	0
78	New treatment possibilities for patients with advanced coronary artery disease and critical limb ischemia – a feasibility study. Postepy W Kardiologii Interwencyjnej, 2016, 4, 368-371.	0.2	0
79	Comparison of long-term outcomes after directional versus rotational atherectomy in peripheral artery disease. Postepy W Kardiologii Interwencyinei, 2020, 16, 76-81.	0.2	0